- DRUGS ON THE MARKET
- FOR TYPE 2 DIABETES:
- Alpha-glucosidase inhibitors
- Biguanides
- DPP-IV inhibitors
- GLP-1 mimetics
- Meglitinides
- Sulfonylureas
- TZDs (thiazolidinediones)
- Combinations
- Other (non-insulin)
- FOR OBESITY:
- Centrally acting
- Lipase inhibitors
DRUGS ON THE MARKET
This page contains a comprehensive list of prescription drugs for obesity and type 2 diabetes that have received regulatory approval in either the US, Europe or Asia.
Drugs are grouped according to the classes listed in the table below. For more detailed information on each drug including dosage information, side-effects, elimination half life, metabolism, US patent status, US FDA status, EMEA status and indication, click on the drug class or on the generic drug name.
FOR TYPE 2 DIABETES:
| Alpha-glucosidase inhibitors | |
| Biguanides |
|
| DPP-IV inhibitors |
|
| GLP-1 mimetics |
|
| Meglitinides |
|
| Sulfonylureas |
|
| TZDs (thiazolidinediones / glitazones) |
|
| Combinations |
|
| Others (non-insulin) |
|
FOR OBESITY:
| Centrally acting |
|
|